Anavex Life Sciences Reports Promising Results from Phase 2 Study in Parkinson’s Disease Dementia
Anavex Life Sciences has announced favorable outcomes from its 48-week open-label extension Phase 2 study of
ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease dementia. The
clinical-stage biopharmaceutical company focuses on developing innovative
therapeutics for neurodegenerative and neurodevelopmental disorders, including
Parkinson’s and Alzheimer’s diseases.
The study, identified as ANAVEX2-73-PDD-EP-001, successfully met both its primary and
secondary objectives. Patients treated with ANAVEX®2-73 demonstrated
significant improvements across all efficacy endpoints. Notably, the treatment
appeared to be generally safe and well-tolerated, aligning with the known
safety profile of ANAVEX®2-73.
Parkinson’s disease affects millions worldwide, and current treatments primarily manage symptoms
without halting disease progression. Anavex aims to address this gap through its lead drug candidate, ANAVEX®2-73,
which targets sigma-1 receptors to restore neural cell homeostasis and promote neuroplasticity.
During the double-blind ANAVEX2-73-PDD-001 Phase 2 study, ANAVEX®2-73 showed statistically
significant improvements in the Movement Disorder Society-Unified Parkinson’s
Disease Rating Scale scores compared to placebo. This promising data was the
foundation for the extension study, where patients continued to experience
clinical benefits over the 48-week period.
Despite a delay in the extension phase due to the COVID-19 pandemic, patients who resumed
ANAVEX®2-73 treatment demonstrated consistent improvements in both motor and
non-motor symptoms after a drug holiday. These results are crucial for Anavex Life Sciences as they plan a forthcoming pivotal trial for
ANAVEX®2-73 in Parkinson’s disease.
The Michael J. Fox Foundation for Parkinson’s Research has also recognized Anavex’s work, awarding
the company a research grant to further investigate ANAVEX®2-73 through
imaging-focused clinical trials. This support emphasizes the potential of
ANAVEX®2-73 as a disease-modifying therapeutic option for Parkinson’s disease
and related neurodegenerative disorders. Visit this page on LinkedIn, to learn more.
More about Anavex on https://www.clinicaltrialsarena.com/news/anavex-data-trial-alzheimers/